IBB small-caps reduce negative returns for December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns. It outperformed the SPDR S&P 500 ETF (SPY) and IBB itself. IBB small-cap stock accounts for ~9.8% of IBB’s portfolio.
As of December 21, IBB holds 78 small-cap stocks in its portfolio. The good performance of the small-cap stocks was the result of 53 of IBB’s 78 small-cap stocks giving positive returns. The small-cap space includes Ironwood Pharmaceuticals (IRWD), Clovis Oncology (CLVS), and Sarepta Therapeutics (SRPT) with returns of -1.6%, 2%, and 0.85%, respectively.
The above graph reflects the returns of IBB’s small-caps along with IBB and SPY. In the month of December so far, IBB small-caps have returned -1.8% compared to SPY’s return of -3.3% and IBB’s return of -0.35%.
Amicus rises 6%
Amicus Therapeutics (FOLD) rose 6% on December 21 and closed at $9.67. The stock was trading 19.2% below the 100-day moving average and 4.6% below the 20-day moving average. The stock witnessed a lower trading volume of ~1.6 million shares compared to the five-day average trading volume of 3.1 million shares per day.
Year-to-date, FOLD has given a return of 16.3%. The stock has an RSI (Relative Strength Index) of 44, which indicates the stock is neither overbought nor oversold. FOLD has a book value of $3.04 per share. With its current value, the stock is trading at a price-to-book value (or PBV) of 3.18x. FOLD has a weight of ~0.2% in IBB’s portfolio.